Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Medicines Company Is Almost Ready To Celebrate Angiomax Patent Term Extension

This article was originally published in The Pink Sheet Daily

Executive Summary

Studies of additional indications for the product may resume as the Patent and Trademark Office assesses the potential length of the extension, which could protect the product until mid-2015.

You may also be interested in...



Angiomax Generic From Hospira Might Launch At-Risk Launch In 2015

District Court upholds validity of TMC’s process patents for its anticoagulant but finds Hospira does not infringe them.

Patent Reform Clears House, But Provisions On PTO Fees, Patent Term Extension Differ From Senate

The Medicines Company and the Appropriations Committee score victories as the House clears the bill by a vote of 304 to 117.

Patent Reform Clears House, But Provisions On PTO Fees, Patent Term Extension Differ From Senate

The Medicines Company and the Appropriations Committee score victories as the House clears the bill by a vote of 304 to 117.

Related Content

Topics

UsernamePublicRestriction

Register

PS071401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel